Table I.
Demographic data for patients and controls
| Characteristic | Patients (n = 31) | Controls (n = 34) |
|---|---|---|
| Age (y; median [range]) | 66 (36–84) | 62 (49–81) |
| ≤60 | 36% (11/31) | 38% (13/34) |
| >60 | 64% (20/31) | 62% (21/34) |
| Men/women | 12/19 | 22/12 |
| Previous unvaccinated patients | 32% (10/31) | 29% (10/34) |
| NHL histotype at diagnosis | ||
| Aggressive | 58% (18/31) | |
| Diffuse large B cell | 42% (13/31) | |
| Others | 16% (5/31) | |
| Indolent | 42% (13/31) | |
| Follicular | 26% (8/31) | |
| Others | 16% (5/31) | |
| Applied chemotherapy regimens (in addition to rituximab) | ||
| CHOP or CHOP likea | 65% (20/31) | |
| CVP | 13% (4/31) | |
| Fludarabine-containing regimensb | 26% (8/31) | |
| Othersc | 23% (7/31) | |
| Lines of chemotherapy administered (n) | ||
| 1 | 84% (26/31) | |
| 2d | 6% (2/31) | |
| 3e | 10% (3/31) | |
| Time after treatment administration (mo; median [range]) | 29 (7–65) | |
| ≤12 | 19% (6/31) | |
| >12 | 81% (25/31) | |
| Rituximab doses (n; median [range]) | 6 (3–11) | |
| ≤6 | 81% (25/31) | |
| >6 | 19% (6/31) | |
| Radiotherapy | 32% (10/31) | |
| Abs serum level | ||
| IgG serum level (mg/dl; median, IQR [normal range]) | 842, 525–1043 (700–1600) | |
| Low serum IgG | 36% (11/31) | |
| IgA serum level (mg/dl; median; IQR [normal range]) | 148, 60–239 (70–400) | |
| Low serum IgA | 26% (8/31) | |
| IgM serum level (mg/dl; median; IQR [normal range]) | 39, 18–78 (40–230) | |
| Low serum IgM | 52% (16/31) | |
| Low IgG or IgA or IgM serum level | 55% (17/31) | |
| Low IgG, IgA, and IgM serum levels | 19% (6/31) | |
Etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (n = 3).
Fludarabine, cyclophosphamide, vincristine, and prednisone (n = 1); fludarabine, mitoxantrone, and cyclophosphamide (n = 4); fludarabine and mitoxantrone (n = 2); and fludarabine and cyclophosphamide (n = 1).
Cyclophosphamide, mesna, methotrexate, doxorubicin, vincristine, cytarabine, and leucovorin (n = 2); cisplatin, etoposide, and mitoxantrone (n = 1); cyclophosphamide (n = 1); cyclophosphamide and dexamethasone (n = 1); gemcitabine and oxaliplatin (n = 1); and cyclophosphamide, vincristine, methotrexate, and prednisone (n = 1).
First line, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; second line, rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (n = 1). First line, fludarabine, mitoxantrone, and cyclophosphamide; second line: rituximab-cyclophosphamide, vincristine, and prednisone (n = 1).
First line, fludarabine, cyclophosphamide, vincristine and prednisone; second line, cisplatin, VP16, and mitoxantrone; third line, rituximab-cyclophosphamide (n = 1). First line, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; second line, rituximab-fludarabine, mitoxantrone, and cyclophosphamide; third line, rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (n = 1). First line, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; second line, rituximab-gemcitabine and oxaliplatin; third line, fludarabine, mitoxantrone, and cyclophosphamide (n = 1).
CVP, cyclophosphamide, vincristine, and prednisone.